Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Galabova, Gergana ^a   Brunner, Sylvia ^a   Winsauer, Gabriele ^a   Juno, Claudia ^a   Wanko, Bettina ^a,b   Mairhofer, Andreas ^a   Lührs, Petra ^a   Schneeberger, Achim ^a   Von Bonin, Arne ^a   Mattner, Frank ^a   Schmidt, Walter ^a   Staffler, Guenther ^a  

^a AFFiRiS GmbH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE VACCINE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 VACCINE; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMORAL IMMUNITY; HYPERCHOLESTEROLEMIA; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; RAT; TREATMENT RESPONSE; 129 MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; IMMUNOLOGY; TRANSGENIC MOUSE; VACCINATION; WISTAR RAT;

ANIMALS; CHOLESTEROL, LDL; FEMALE; HYPERCHOLESTEROLEMIA; MALE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PROPROTEIN CONVERTASES; RATS, WISTAR; SERINE ENDOPEPTIDASES; VACCINATION; VACCINES, SUBUNIT;

EID: 84915746642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114469     Document Type: Article

References (27)

1. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47.
2. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
3. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, et al. (2007) Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282: 18602-18612.
4. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, et al. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14: 413-419.
5. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, et al. (2007) The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15: 545-552.
6. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, et al. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 283: 2363-2372.
7. Fisher TS, Surdo PL, Pandit S, Mattu M, Santoro JC, et al. (2007) Effects of pH and Low Density Lipoprotein (LDL) on PCSK9-dependent LDL Receptor Regulation. J Biol Chem 282: 20502-20512.
8. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, et al. (2006) Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 15: 1551-1558.
9. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, et al. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 100: 928-933.
10. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156.
11. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, et al. (2009) Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120: 28-34.
12. Chong PH, Bachenheimer BS (2000) Current, new and future treatments in dyslipidaemia and atherosclerosis. Drugs 60: 55-93.
13. Marais DA, Blom DJ, Petrides F, Goueffic Y, Lambert G (2012) Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 23: 511-517.
14. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, et al. (2012) Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 366: 1108-1118.
15. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, et al. (2013) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380: 2007-2017.
16. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, et al. (2012) Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/ REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy. J Am Coll Cardiol 59: 2344-2353.
17. Desai NR, Kohli P, Giugliano RP, O'Donoghue M, Somaratne R, et al. (2013) AMG 145, A Monoclonal Antibody Against PCSK9, Significantly Reduces Lipoprotein (a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LAPLACE-TIMI 57 Trial. Circulation 128: 962-969.
18. Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Verheyen F, et al. (2012) Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 56: 894-903.
19. Ryan US, Rittershaus CW (2006) Vaccines for the prevention of cardiovascular disease. Vascul Pharmacol 45: 253-257.
20. Lu X, Xia M, Endresz V, Faludi I, Szabo A, et al. Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice. Atherosclerosis 225: 56-68.
21. Fattori E, Cappelletti M, Lo Surdo P, Calzetta A, Bendtsen C, et al. (2012) Immunization against Proprotein Convertase Subtilisin-like/Kexin type 9 (PCSK9) lowers plasma LDL-cholesterol levels in mice. J Lipid Res 53: 1654-1661.
22. Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, et al. (2012) An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes. Int J Biol Sci 8: 310-327.
23. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, et al. (2009) Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J Nutr Health Aging 13: 264-267.
24. Do RQ, Vogel RA, Schwartz GG (2013) PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics. Curr Cardiol Rep 15: 345.
25. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, et al. (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27: 1706-1721.
26. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, et al. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102: 5374-5379.
27. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20.